Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

TG-1202: Ph III ongoing

Julian Zhu
December 2, 2016 7:34 PM UTC

An independent DSMB recommended continuation of the open-label, international Phase III UNITY-CLL trial comparing IV ublituximab (TG-1101) and oral TGR-1202 alone or in combination vs. IV Gazyva obinutuzumab plus oral chlorambucil based on safety data. Patients will receive ublituximab on days 1, 8 and 15 followed by maintenance infusions and TGR-1202 once daily. TG Therapeutics has an SPA from FDA for the trial, which is enrolling about 450 patients...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Rhizen Pharmaceuticals S.A.

Tg Therapeutics Inc.